Elimination of hepatitis B virus (HBV) is infrequently achieved with current therapies. Therefore, more effective anti-HBV therapy is needed. We previously reported that geranylgeranylacetone (GGA) showed anti-hepatitis C virus activity in human hepatoma cells. In this study, we examined the anti-HBV activity of GGA.

Authors: Masafumi Haraguchi, Satoshi Miuma, Kazuo Yamamoto, Yasuhiko Nakao, Tatsuki Ichikawa, Yasuko Kanda, Ryu Sasaki, Masanori Fukushima, Yuko Akazawa, Hisamitsu Miyaaki, Kazuhiko Nakao

Read publication

Back to Resources